Harbor Capital Advisors Inc. bought a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 42,185 shares of the company's stock, valued at approximately $1,954,000. Harbor Capital Advisors Inc. owned approximately 0.08% of LivaNova as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of LIVN. Canada Pension Plan Investment Board purchased a new stake in LivaNova in the 2nd quarter valued at about $88,000. Central Pacific Bank Trust Division bought a new position in shares of LivaNova in the third quarter valued at approximately $178,000. Captrust Financial Advisors purchased a new stake in shares of LivaNova during the third quarter valued at approximately $217,000. Sanctuary Advisors LLC bought a new stake in LivaNova during the third quarter worth $219,000. Finally, Edgestream Partners L.P. purchased a new position in LivaNova in the third quarter worth $244,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Insider Activity at LivaNova
In other news, Director Francesco Bianchi sold 1,250 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.
LivaNova Stock Performance
Shares of LIVN traded down $1.38 during trading hours on Friday, hitting $46.66. The company's stock had a trading volume of 337,088 shares, compared to its average volume of 368,231. The business has a 50 day simple moving average of $49.82 and a two-hundred day simple moving average of $50.31. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.53 billion, a price-to-earnings ratio of 111.10 and a beta of 1.01.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. Robert W. Baird increased their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Finally, StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 25th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $69.17.
Check Out Our Latest Analysis on LIVN
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
